Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Analgesic

or Anticonvulsant

or [[:Category:Benzodiazepines|Benzodiazepine (long-acting)]]

Use the filters below to narrow your results.

Brivaracetam (1) · Buprenorphine (1) · Butorphanol (1) · Cannabidiol (1) · Cenobamate (1) · Clobazam (1) · Codeine (2) · Dextropropoxyphene (1) · Diazepam (1) · Dihydrocodeine (1) · Eslicarbazepine (1) · Ethosuximide (1) · Ethylmorphine (1) · Felbamate (1) · Fenfluramine (1) · Fentanyl (1) · Fosphenytoin (1) · Hydrocodone (1) · Hydromorphone (1) · Lacosamide (1) · Levorphanol (1) · Meperidine (1) · Methadone (1) · Nalbuphine (1) · Oxymorphone (1) · Papaverine (1) · Pentazocine (1) · Perampanel (1) · Phenobarbital (1) · Phenytoin (1) · Rufinamide (1) · Stiripentol (1) · Tapentadol (1) · Tiagabine (1) · Valproic acid (1) · Vigabatrin (1) · Zonisamide (1)

None (5) · (multiple, generic dominant) (1) · Aptiom (1) · Banzel (1) · Briviact (1) · Cerebyx (1) · Darvon (1) · Demerol (1) · Depakote (1) · Diacomit (1) · Dilantin (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · Epidiolex (1) · Felbatol (1) · Fintepla (1) · Fycompa (1) · Gabitril (1) · Luminal (1) · Nubain (1) · Nucynta (1) · Onfi (1) · Opana (1) · Sabril (1) · Stadol (1) · Suboxone (1) · Talwin (1) · Valium (oral, IV/IM, rectal), Diastat (rectal gel for breakthrough seizures), Valtoco (nasal spray for breakthrough seizures), Libervant (buccal film) (1) · Vicodin (1) · Vimpat (1) · Xcopri (1) · Zarontin (1) · Zonegran (1)

None (1) · AMPA receptor antagonist (1) · GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) · GABA reuptake inhibitor (GAT-1 blocker) (1) · GABAA positive allosteric modulator (1) · GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) · GABAA potentiator and direct activator (1) · Irreversible GABA-T inhibitor (1) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; NMDA antagonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) · NMDA antagonist; GABAA potentiator (1) · Partial mu-opioid agonist; kappa antagonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Prodrug of phenytoin; sodium channel blocker (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Serotonin releaser; sigma-1 agonist (1) · Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) · Sodium channel blocker (2) · Sodium channel blocker; GABAA positive allosteric modulator (1) · Sodium channel modulator (1) · Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) · SV2A ligand (higher affinity than levetiracetam) (1) · T-type calcium channel blocker (1)

None (36) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (1)

None (36) · Adult: 15–60 mg every 4 hours as needed. (1) · Anxiety: 2-10 mg PO 2-4 times daily. Alcohol withdrawal: 10-20 mg PO/IV every 4-6 hours, symptom-triggered. Status epilepticus: 5-10 mg IV. Breakthrough seizures: Diastat rectal 0.2-0.5 mg/kg or Valtoco intranasal 5-20 mg (1)

None (36) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1) · Tablets 2, 5, 10 mg; oral solution 1, 5 mg/mL; injection 5 mg/mL; Diastat rectal gel 2.5, 5, 10, 20 mg; Valtoco nasal spray 5, 7.5, 10 mg/dose; Libervant buccal film (1)

None (36) · 360 mg/day (1) · 40 mg/day (oral, anxiety) (1)

None (36) · buccal (1) · IM (1) · intranasal (1) · IV (1) · Oral (1) · PO (only formulation marketed in the US). (1) · rectal (1)

None (36) · 15-60 minutes (oral); 1-5 minutes (IV); 4-10 minutes (rectal or intranasal) (1) · 30–60 min (PO) (1)

None (36) · 4–6 hours (1) · 6-24 hours (parent); much longer when accounting for the long-lived active metabolites (1)

None (36) · 2.5–3 hours (1) · Diazepam 20-50 hours; '''N-desmethyldiazepam (nordazepam) 30-200 hours''' is the major active metabolite and accumulates substantially with chronic dosing'"`UNIQ--ref-00000026-QINU`"' (1)

None (36) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~93% (oral); ~90% (rectal)'"`UNIQ--ref-00000027-QINU`"' (1)

None (36) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Some signal for cleft palate with first-trimester exposure (debated); neonatal sedation and withdrawal with third-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (36) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Schedule IV|Schedule IV controlled substance]] in US. Carries the benzodiazepine class '''Boxed Warning''' for risk of fatal respiratory depression, coma, and death when combined with opioids'"`UNIQ--ref-00000028-QINU`"' (1)